{
    "clinical_study": {
        "@rank": "40109", 
        "arm_group": {
            "arm_group_label": "All Participants", 
            "description": "Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX\u00ae) according to general clinical practice."
        }, 
        "brief_summary": {
            "textblock": "This retrospective chart review study will describe the history of patients with retinal\n      disease with macular edema to whom OZURDEX\u00ae (dexamethasone intravitreal implant) is\n      administered, and assess treatment patterns and visual outcomes. OZURDEX\u00ae was previously\n      administered according to general clinical practice."
        }, 
        "brief_title": "A Retrospective Chart Review of OZURDEX\u00ae in Patients With Macular Edema", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX\u00ae) according to general clinical practice.", 
                        "title": "All Participants"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "101"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "14.8", 
                                            "@value": "60.9"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "35"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "66"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). The peak mean change in BCVA was calculated using the most improved number of lines read correctly between 2 and 26 weeks following the last available injection of OZURDEX\u00ae - the number of lines read correctly at Baseline. A positive change from Baseline indicated improvement.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX\u00ae) according to general clinical practice.", 
                                "title": "All Participants"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "78"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "90"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Eyes analyzed", 
                                    "units": "Eyes"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.3", 
                                                        "@value": "6.3"
                                                    }
                                                }, 
                                                "sub_title": "Baseline"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.3", 
                                                        "@value": "1.4"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline 2-26 wks after last injection"
                                            }
                                        ]
                                    }, 
                                    "description": "BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). The peak mean change in BCVA was calculated using the most improved number of lines read correctly between 2 and 26 weeks following the last available injection of OZURDEX\u00ae - the number of lines read correctly at Baseline. A positive change from Baseline indicated improvement.", 
                                    "dispersion": "Standard Error", 
                                    "param": "Mean", 
                                    "title": "Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)", 
                                    "units": "Lines"
                                }
                            ]
                        }, 
                        "population": "All participants with BCVA observations available following the last OZURDEX\u00ae injection from 2 to 26 weeks.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, 2 to 26 weeks (wks) following last injection (up to 6.5 months)", 
                        "title": "Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye. The peak mean change was the maximum change from Baseline in CRT at 2 to 26 weeks following the last available injection of OZURDEX\u00ae. A negative change from Baseline indicated improvement.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX\u00ae) according to general clinical practice.", 
                                "title": "All Participants"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "75"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "85"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Eyes analyzed", 
                                    "units": "Eyes"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "18.2", 
                                                        "@value": "474.4"
                                                    }
                                                }, 
                                                "sub_title": "Baseline"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "17.9", 
                                                        "@value": "-183.4"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline 2-26 wks after last injection"
                                            }
                                        ]
                                    }, 
                                    "description": "Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye. The peak mean change was the maximum change from Baseline in CRT at 2 to 26 weeks following the last available injection of OZURDEX\u00ae. A negative change from Baseline indicated improvement.", 
                                    "dispersion": "Standard Error", 
                                    "param": "Mean", 
                                    "title": "Peak Mean Change From Baseline in Central Retinal Thickness (CRT)", 
                                    "units": "microns (\u03bcm)"
                                }
                            ]
                        }, 
                        "population": "All participants with CRT observations available following the last OZURDEX\u00ae injection from 2 to 26 weeks.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, 2 to 26 weeks following last injection (up to 6.5 months)", 
                        "title": "Peak Mean Change From Baseline in Central Retinal Thickness (CRT)", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX\u00ae) according to general clinical practice.", 
                        "title": "All Participants"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "101", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "101", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "clinicaltrials@allergan.com", 
                "name_or_title": "Vice President  Medical Affairs,", 
                "organization": "Allergan, Inc", 
                "phone": "714-246-4500"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX\u00ae) according to general clinical practice.", 
                        "title": "All Participants"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "25", 
                                            "@subjects_at_risk": "101"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "6", 
                                            "@subjects_at_risk": "101"
                                        }, 
                                        "sub_title": "Cystoid macular oedema"
                                    }
                                }, 
                                "title": "Eye disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "19", 
                                            "@subjects_at_risk": "101"
                                        }, 
                                        "sub_title": "Intraocular pressure increased"
                                    }
                                }, 
                                "title": "Investigations"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA 16.0", 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "4", 
                                            "@subjects_at_risk": "101"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "101"
                                            }, 
                                            "sub_title": "Endophthalmitis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "101"
                                            }, 
                                            "sub_title": "Uveitis"
                                        }
                                    ]
                                }, 
                                "title": "Eye disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "101"
                                        }, 
                                        "sub_title": "Retinal detachment"
                                    }
                                }, 
                                "title": "Injury, poisoning and procedural complications"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "101"
                                        }, 
                                        "sub_title": "Retinal implant"
                                    }
                                }, 
                                "title": "Surgical and medical procedures"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA 16.0"
                }
            }
        }, 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Retinal disease involving macular edema\n\n          -  Received at least one OZURDEX\u00ae injection\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with macular edema"
            }
        }, 
        "enrollment": {
            "#text": "101", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "firstreceived_results_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805323", 
            "org_study_id": "CMA-OZU-12-001"
        }, 
        "intervention": {
            "arm_group_label": "All Participants", 
            "description": "Dexamethasone Intravitreal Implant (OZURDEX\u00ae) previously administered according to general clinical practice.", 
            "intervention_name": "Dexamethasone Intravitreal Implant", 
            "intervention_type": "Drug", 
            "other_name": "OZURDEX\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Quebec City", 
                    "country": "Canada", 
                    "state": "Quebec"
                }
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). The peak mean change in BCVA was calculated using the most improved number of lines read correctly between 2 and 26 weeks following the last available injection of OZURDEX\u00ae - the number of lines read correctly at Baseline. A positive change from Baseline indicated improvement.", 
            "measure": "Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 2 to 26 weeks (wks) following last injection (up to 6.5 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805323"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye. The peak mean change was the maximum change from Baseline in CRT at 2 to 26 weeks following the last available injection of OZURDEX\u00ae. A negative change from Baseline indicated improvement.", 
            "measure": "Peak Mean Change From Baseline in Central Retinal Thickness (CRT)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 2 to 26 weeks following last injection (up to 6.5 months)"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}